ID
13480
Description
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5) Description of Form: Baseline Concomitant Diseases Form
Keywords
Versions (3)
- 11/10/15 11/10/15 -
- 12/23/15 12/23/15 -
- 2/11/16 2/11/16 -
Uploaded on
February 11, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Baseline Concomitant Diseases Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26
Baseline Concomitant Diseases Form
- StudyEvent: ODM
Similar models
Baseline Concomitant Diseases Form
- StudyEvent: ODM
C0750480 (UMLS CUI [1,2])
C0460002 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,2])
C0205177 (UMLS CUI [1,2])
C1442488 (UMLS CUI [1,3])
C0441800 (UMLS CUI [1,2])